Laboratory of Biomaterials and Translational Medicine, Department of Urology, The Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510630, China.
J Mater Chem B. 2021 Jan 7;9(1):23-34. doi: 10.1039/d0tb02094j. Epub 2020 Nov 12.
Interstitial cystitis/bladder pain syndrome (IC/BPS) is a chronic and painful bladder condition afflicting patients with increased urinary urgency and frequency as well as incontinence. Owing to the elusive pathogenesis of IC/BPS, obtaining effective therapeutic outcomes remains challenging. Current administrational routes such as intravesical-bladder injection improve the treatment efficacy and reduce systemic side effects. However, the bladder permeability barrier hinders drug penetration into the bladder wall to meet the desired therapeutic expectation. These issues can be addressed by encapsulating drugs into biomaterials. When appropriately exploited, they would increase the drug dwelling time in the bladder, enhance the penetration of mucosa and improve the therapeutic response of IC/BPS. In this review, we first elucidate the pathogenesis and animal models of IC/BPS. Then, we highlight recent representative biomaterial-assisted drug delivery systems for IC/BPS treatment. Finally, we discuss the challenges and outlook for further developing biomaterial-based delivery systems for IC/BPS management.
间质性膀胱炎/膀胱疼痛综合征(IC/BPS)是一种慢性且疼痛的膀胱疾病,患者会出现尿急、尿频和失禁等症状。由于 IC/BPS 的发病机制难以捉摸,因此获得有效的治疗效果仍然具有挑战性。目前的管理途径,如膀胱内注射,可以提高治疗效果并减少全身副作用。然而,膀胱通透性屏障会阻碍药物渗透到膀胱壁,从而无法达到预期的治疗效果。通过将药物包裹在生物材料中可以解决这些问题。如果得到合理利用,这些生物材料可以增加药物在膀胱中的停留时间,增强黏膜穿透性,并改善 IC/BPS 的治疗反应。在这篇综述中,我们首先阐述了 IC/BPS 的发病机制和动物模型。然后,我们重点介绍了最近用于治疗 IC/BPS 的代表性生物材料辅助药物传递系统。最后,我们讨论了进一步开发用于 IC/BPS 管理的基于生物材料的输送系统所面临的挑战和展望。